[Utility of 90Y-Ibritumomab Tiuxetan (Zevalin) in the treatment of adult patients with non-Hodgkin lymphoma]
Ramos Font C, Rebollo Aguirre AC, Villegas Portero R
Record ID 32010001468
Spanish
Authors' recommendations:
There are few phase III clinical trials, and publications derived from them, which evaluate the utility of 90Y-Ibritumomab Tiuxetan as a therapeutic option in NHL patients. Radioimmunotherapy (RIT) with 90Y-Ibritumomab Tiuxetan prolongs the time to relapse and the global survival of patients with indolent NHL. However, the information available at the present time is insuffi cient to determine the risk/benefi t ratio derived from the addition of 90Y-Ibritumomab Tiuxetan to the present standard chemotherapy-rituximab treatment. It would be advisable to wait for the trials currently underway to be completed to confi rm the preliminary results obtained.
Details
Project Status:
Completed
URL for project:
https://www.aetsa.org/publicacion/utilidad-del-90y-ibritumomab-tiuxetan-zevalin-en-el-tratamiento-de-pacientes-adultos-con-linfoma-no-hodgkin/
Year Published:
2010
URL for published report:
https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2007-15_zevalin.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Lymphoma, Non-Hodgkin
- Radioimmunotherapy
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.